drospirenone/ethinylestradiol (Rx)Brand and Other Names:Yasmin, Yaz, more...Gianvi, Beyaz, Loryna, Ocella, Syeda, Safyral, Vestura, Zarah

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 3mg/0.02mg (Yaz, Gianvi, Loryna, Vestura)
  • 3mg/0.02mg plus 0.451mg levomefolate (Beyaz)
  • 3mg/0.03mg (Yasmin, Syeda, Zarah)
  • 3mg/0.03mg plus 0.451mg levomefolate (Safyral)
more...

Contraception

Yasmin, Ocella, Zarah, Safyral, Syeda

  • 1 active tablet (3 mg drospirenone/0.03 mg EE) PO qDay for 21 days, THEN 1 inert tablet PO qDay for 7 days

Yaz, Beyaz, Gianvi, Loryna, Vestura

  • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Dosing considerations

  • Women should be advised to use additional nonhormonal contraception during the first 7 days of therapy
  • Administer tablets in the order directed on the blister pack calendar at the same time each day
  • Increased risk for venous thromboembolism (VTE) with combined hormonal contraceptives following delivery; risk declines rapidly after 21 days but does not return to normal until 42 days after delivery
  • CDC guidelines recommend waiting 21-42 days to initiate therapy in postpartum women without additional VTE risks (MMWR July 7, 2011)
  • Postpartum women who do not breastfeed or after a second trimester abortion: Wait ≥4 weeks to initiate therapy
  • Postpartum women who have had a caesarean section birth: Wait ≥6 weeks to initiate therapy
  • Women with other risk factors for VTE in addition to postpartum: Do not use combined hormonal contraceptives

Moderate Acne Vulgaris

Yaz, Gianvi, Beyaz, Loryna

  • Moderate acne in women, but only if oral contraceptive is chosen as method of birth control
  • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Dosing considerations

  • Administer tablets in the order directed on the blister pack calendar at the same time each day

Premenstrual Dysphoric Disorder

Yaz, Beyaz, Gianvi

  • Symptoms of premenstrual dysphoric disorder (PMDD), but only if oral contraceptive is chosen as method of birth control
  • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Dosing considerations

  • Administer tablets in the order directed on the blister pack calendar at the same time each day

Dosing Modifications

Renal impairment: Contraindicated

Hepatic impairment: Contraindicated

Dosage Forms & Strengths

tablet

  • 3mg/0.02mg (Yaz, Gianvi, Loryna, Vestura)
  • 3mg/0.02mg plus 0.451mg levomefolate (Beyaz)
  • 3mg/0.03mg (Yasmin, Syeda, Zarah)
  • 3mg/0.03mg plus 0.451mg levomefolate (Safyral)
more...

Contraception

<14 years: Safety and efficacy not established

>14 years: Same dosing as adult

Moderate Acne Vulgaris

Moderate acne in females ≥14 years, but only if oral contraceptive is chosen as method of birth control

Same dosages as in adults

Next

Interactions

Interaction Checker

drospirenone/ethinylestradiol and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Premenstrual syndrome (13.2%)

            Migraine/headache (10.7%)

            1-10%

            Breast pain/discomfort/tenderness (8.3%)

            Menstrual irregularities (4.7%)

            Nausea/vomiting (4.5%)

            Abdominal pain/discomfort/tenderness (2.3%)

            Mood changes, including affect lability, depression, alteration of mood, mood swings, and irritability (2.3%)

            Frequency Not Defined

            Irregular uterine bleeding

            Venous/arterial thromboembolic events, including DVT, PE, stroke, MI, intracardiac thrombosis, sagittal sinus thrombosis, intracranial venous sinus thrombosis, retinal vein thrombosis

            Hypertension

            Hypersensitivity

            Hyperkalemia

            Chloasma

            Gallbladder disease

            Toxic skin eruption

            Uterine leiomyoma

            Previous
            Next

            Warnings

            Black Box Warnings

            Cigarette smoking and risk of cardiovascular disease

            • Women >35 years who smoke should not use oral contraceptives
            • Cigarette smoking increases risk of serious cardiovascular adverse effects from combination oral contraceptive use
            • This risk increases with age (>35 yr) and with heavy smoking (15 or more cigarettes/day)
            • Advise women taking oral contraceptives not to smoke

            Contraindications

            Documented hypersensitivity

            Active/history of breast cancer or estrogen- or progestin-sensitive caner

            Active/history of arterial thromboembolic disease (stroke, MI), thrombophlebitis, DVT/PE, thrombogenic valvular disease

            Uncontrolled hypertension

            Diabetes mellitus with vascular involvement

            History of migraine with aura

            Undiagnosed abnormal uterine bleeding

            Benign or malignant liver tumors, hepatic impairment or development of jaundice with prior oral contraceptive use

            Pregnancy

            Renal impairment

            Adrenal insufficiency

            Cautions

            Due to increased risk of hyperkalemia, monitor serum potassium during first month if coadministered with potassium-elevating/sparing drugs (eg, spironolactone); consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly; strong CYP3A4 inhibitors include azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV/HCV protease inhibitors (e.g., indinavir, boceprevir), and clarithromycin

            Family history of breast cancer and or DVT/PE

            Current/history of depression, endometriosis, DM, HTN, bone mineral density changes, renal/hepatic impairment, bone metabolic disease, SLE

            Conditions exacerbated by fluid retention (eg, migraine, asthma, epilepsy)

            Discontinue immediately if any of the following occur: jaundice, visual problems (may cause contact lens intolerance), any signs of VTE, migraine with unusual severity, significant increase in BP, severe depression, increased risk of thromboembolic complications after surgery

            Discontinue therapy 4 weeks before major surgery or prolonged immobilization; may resume 2 weeks afterwards

            Monitor patients on oral anticoagulants (eg, warfarin); increased anticoagulant dose may be warranted due to thromboembolic risk with oral contraceptives

            Some studies have shown a link between the use of oral contraceptive pills (OCPs) and increased risk of breast cancer, whereas other studies have not; risk depends on conditions in which naturally high hormone levels persist for long periods of time, including early onset menstruation before age 12 years, late-onset menopause, age ≥55 years, first child born after age 30 years, nulliparity

            Studies have shown an increased risk of cervical cancer with OCP use; however, HPV remains the main risk factor for cervical cancer; evidence suggests long-term use of OCPs (≥5 yr) may be associated with increased risk

            Studies have shown a significantly decreased endometrial cancer risk with OCP use; protective effect increases with longer duration of OCP use and may continue to persist years after OCP discontinuation

            Risk of ovarian cancer may decrease with increasing duration of OCP use

            Increased risk of liver cancer with OCP use; risk increases with longer duration of OCP use

            Monitor prediabetic and diabetic women with dyslipidemias

            Thromboembolic disorders

            • Discontinue immediately if thrombotic event occurs
            • Risk of VTE is highest during the first year of use; interim data from a large, prospective cohort safety study of various combined oral contraceptives (COCs) suggest that this increased risk, as compared with that in non-COC users, is greatest during the first 6 months of COC use
            • Women taking drospirenone-containing contraceptives may have up to a 3-fold increased risk for developing VTE compared with women taking other combined hormonal contraceptives
            • To decrease risk of VTE events, CDC guidelines recommend waiting at least 3 weeks following vaginal birth or 6 weeks after cesarean section before initiating use of combined hormonal contraceptives; women with additional risk factors for VTE (besides postpartum) should not use combined hormonal contraceptives
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: X

            Lactation: Small amounts of steroids are excreted in breast milk; estrogens may reduce quality/quantity of milk; may be prudent to use other forms of birth control until full weaning (AAP Committee states compatible with nursing)

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Ethinyl estradiol: Reduces LHRH release from hypothalamus, reduces gonadotropin release from pituitary; increases synthesis of DNA, RNA, and various proteins in target tissues; other possible mechanisms include changes in cervical mucus that cause inhibition of sperm penetration and endometrial changes that reduce likelihood of implantation

            Drospirenone: Progestin; spironolactone analogue with anti-mineralocorticoid and anti-androgenic activity

            Absorption

            Bioavailability: 76% (drospirenone); 40% (ethinyl estradiol)

            Peak plasma time: 1-2 hr

            Peak plasma concentration: 88 ng/mL (drospirenone); 99 pg/mL (ethinyl estradiol)

            AUC: 830-970 ng.hr/mL (drospirenone); 350-470 pg.hr/mL (ethinyl estradiol)

            Distribution

            Protein bound

            • Ethinyl estradiol: >98% bound to serum albumin
            • Drospirenone: 97% bound to serum proteins (not SHBG or corticosteroid-binding globulin)

            Metabolism

            Hepatic metabolization

            Metabolites: Two acid forms of DSRP (inactive)

            Elimination

            Half-life: 24 hr (ethinyl estradiol); 30 hr (drospirenone)

            Excretion: Urine (38-47% as inactive metabolites), feces (17-20% as inactive metabolites)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.